glp-1 drugs key developments 2025 RA prescription trends: January 2018 – September GLP-1 Receptor Agonist Market Growth
Description
Adv Clin Chem
10.1136/bmj.q1645 [DOI] [PubMed] [Google Scholar] 10.Gulak MA, Murphy P
Man spricht hier von der Halbwertszeit, die bei GLP-1 vergleichsweise kurz ist
In addition, fewer semaglutide-treated patients experienced deterioration in NYHA functional class (2.09% versus 5.24%, respectively
